Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…
HOME > REGULATORY
REGULATORY
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
- Nobelpharma’s Tympanic Membrane Perforation Treatment Up for MHLW Panel Review on Aug. 1
July 23, 2019
- LDP’s Eto Secures Upper House Seat
July 22, 2019
- PMDA Reviewing Risks for Xeljanz and More
July 22, 2019
- Label Revisions Ordered for Opdivo, Keytruda, Ibrance and More
July 10, 2019
- LDP Lawmaker Seiichi Eto Launches Campaign for Upper House Election
July 5, 2019
- No Discussion in Progress for Health Coverage of Risk Reducing Mastectomies for Breast Cancer: Health Minister
July 4, 2019
- Hayashi of Japan Pension Service Tapped for Economic Affairs Division Director: MHLW Personnel Shakeup
July 3, 2019
- Biosimilar Guidelines Nearing 1st Revision in 10 Years, MHLW Taking Public Comments
July 2, 2019
- JPWA Fears October Price Revision Will “Set Back” Efforts to Improve Distribution Practices, Asks Govt for Support
July 1, 2019
- Eylea Gets Orphan Status for Neovascular Glaucoma
July 1, 2019
- MHLW Data Show Big Improvement in Single-Product, Single-Price Transaction Rates
July 1, 2019
- Feburic Label to Be Revised due to CV Risk, but No Patient Restrictions to Be Required “at Present”
June 28, 2019
- PMD Amendment Bill Put under Continued Diet Review
June 28, 2019
- Chuikyo Reps Give Kudos to Formulary Initiatives, but Wary on Creating Medical Fees
June 27, 2019
- Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
June 27, 2019
- MHLW to Conduct Drug Price Survey before October Tax Hike: Chuikyo
June 27, 2019
- No Established Definition Is in Place for Formulary: Govt
June 27, 2019
- Janssen’s HIV Drug Symtuza to Join NHI Price List on July 3
June 27, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…